Related Experiment Video
Updated: Oct 25, 2025
07:28
Imaging Cell Viability on Non-transparent Scaffolds — Using the Example of a Novel Knitted Titanium Implant
Published on: September 7, 2016
11.5K
Implanted subcutaneous versus intraperitoneal bioscaffold seeded with hepatocyte-like cells: functional evaluation.
Amal Elham Fares1, Hala Gabr2, Asmaa Mohammed ShamsEldeen3
1Histology Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Stem Cell Research & Therapy
|August 7, 2021
Summary
This study developed a novel bioscaffold from decellularized liver seeded with stem cells to produce factor VIII (FVIII) for hemophilia A treatment. Subcutaneous implantation yielded higher FVIII levels than intraperitoneal implantation in rats.
Area of Science:
- Regenerative Medicine
- Biomaterials Engineering
- Hematology
Background:
- Hemophilia A is a bleeding disorder caused by deficient factor VIII (FVIII) production.
- Current FVIII replacement therapy is expensive and can lead to inhibitor formation.
- Stem cells show potential for FVIII secretion, offering a new therapeutic avenue.
Purpose of the Study:
- To create a decellularized liver bioscaffold seeded with trans-differentiated human stem cells.
- To evaluate the efficacy of this bioscaffold for FVIII production in vivo.
- To compare the outcomes of intraperitoneal versus subcutaneous implantation.
Main Methods:
- Decellularized liver bioscaffolds were generated.
- Human stem cells were trans-differentiated into hepatic-like cells and seeded onto scaffolds.
- The resulting organoids were implanted into rats via intraperitoneal or subcutaneous routes.
Main Results:
- Serum human FVIII levels were significantly higher in rats with subcutaneous implants compared to intraperitoneal implants.
- Immunostaining confirmed the presence and maturation of human hepatocytes within the scaffolds.
- Subcutaneous implantation demonstrated superior FVIII production.
Conclusions:
- Implantation of decellularized liver bioscaffolds seeded with stem cells successfully established FVIII production in rats.
- Subcutaneous implantation is a more effective delivery method for achieving higher FVIII levels.
- This approach holds promise for a novel hemophilia A treatment strategy.
